IBDwatch

‘Quality of Care’ Standards in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2018 Nov 13;: Authors: Fiorino G, Allocca M, Chaparro M, Coenen S, Fidalgo C, Younge L, Gisbert JP Abstract Background: Inflammatory bowel disease [IBD] includes chronic, disabling and progressive conditions that need a complex approach and management. Although several attempts have been made to standardize the care of IBD patients, no clear definitions of a global ‘standard of care’ are currently available. Methods: We performed a systematic review of the available literature, searching for all relevant…

The profile of human milk metabolome, cytokines and antibodies in inflammatory bowel diseases versus healthy mothers and potential impact on the newborn. J Crohns Colitis. 2018 Nov 12;: Authors: Meng X, Dunsmore G, Koleva P, Elloumi Y, Wu RY, Sutton RT, Ambrosio L, Hotte N, Nguyen V, Madsen KL, Dieleman LA, Chen H, Huang V, Elahi S Abstract Background and Aims: For women with inflammatory bowel disease (IBD), it is not very well known how IBD or IBD treatment impacts their breastmilk components. We aimed to investigate whether breastmilk composition…

Cannabis, cannabinoids and the endocannabinoid system – is there therapeutic potential for inflammatory bowel disease? J Crohns Colitis. 2018 Nov 12;: Authors: Ambrose T, Simmons A Abstract Cannabis sativa and its extracts have been used for centuries both medicinally and recreationally. There is accumulating evidence that exogenous cannabis and related cannabinoids improve symptoms associated with inflammatory bowel disease such as pain, loss of appetite, and diarrhoea. In vivo, exocannabinoids have been demonstrated to improve colitis, mainly in chemical models.Exocannabinoids signal through the endocannabinoid system, an increasingly understood network of endogenous…